Tebipenem Pivoxil
Brand names: Utebzi · Active ingredient: Tebipenem Pivoxil
In short: UTEBZI is indicated for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae species complex, Klebsiella oxytoca, and Enterococcus faecalis in adult pa
What is Tebipenem Pivoxil used for?
UTEBZI is indicated for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae species complex, Klebsiella oxytoca, and Enterococcus faecalis in adult patients who have limited or no alternative oral treatment options.
To reduce the development of drug‑resistant bacteria and maintain the effectiveness of UTEBZI and other antibacterial drugs, UTEBZI should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Tebipenem Pivoxil dosage
The recommended dosage of UTEBZI is 600 mg (two 300 mg tablets) administered orally every 6 hours for 7 to 10 days in adult patients with an estimated glomerular filtration rate (eGFR) between 60 and 150 mL/min. Do not use UTEBZI beyond the recommended treatment duration .
UTEBZI can be taken with or without food .
Use of UTEBZI is not recommended in patients with eGFR >150 mL/min because it is predicted to decrease tebipenem exposure which may reduce UTEBZI efficacy .
The recommended dosage of UTEBZI for patients with renal impairment is presented in Table 1. There are insufficient data available to determine dosing in hemodialysis patients [see Warnings and Precautions (5.4), Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].
Estimated Glomerular Filtration Rate (GFR) | Dose | Frequency
60 mL/min to less than 90 mL/min | 600 mg | Every 6 hours
30 mL/min to 59 mL/min | 300 mg | Every 6 hours
15 mL/min to 29 mL/min | 300 mg | Every 12 hours
Swallow UTEBZI whole and administer with or without food .
If a dose is missed, instruct patients to take the missed dose as soon as possible. Do not double the dose to make up for a missed dose.
How to take Tebipenem Pivoxil — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Hypersensitivity Reactions
Advise patients that hypersensitivity, including serious hypersensitivity reactions, could occur, and that serious hypersensitivity reactions require immediate treatment. Advise patients to inform their healthcare provider about any previous hypersensitivity reactions to carbapenems, penicillins, cephalosporins, other beta‑lactam antibacterials and other allergens .
Seizures and Central Nervous System Reactions
Advise patients that central nervous system (CNS) reactions have been reported during treatment with beta‑lactam antibacterials. If CNS adverse reactions, including seizures, occur, advise patients to inform their healthcare provider to determine whether UTEBZI should be discontinued .
Drug Interaction with Valproic Acid
Advise patients to avoid concomitant use with valproic acid or valproate . …
Warnings & precautions
Do not take this medicine if: UTEBZI is contraindicated in patients with hypersensitivity to UTEBZI or other beta‑lactam antibacterial drugs .
UTEBZI is contraindicated in patients with primary or secondary carnitine deficiency or inborn errors of metabolism that may result in clinically significant carnitine deficiency .
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta‑lactam and carbapenem antibacterials. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens. Assess patients for previous hypersensitivity reactions to carbapenems, penicillins, cephalosporins, or other beta-lactams before initiating treatment with UTEBZI. If an allergic reaction to UTEBZI occurs, discontinue UTEBZI and institute appropriate supportive measures.
Seizures and other central nervous system (CNS) adverse reactions have been reported in patients receiving therapy with beta-lactam and carbapenem antibacterials, including UTEBZI. These adverse reactions occurred most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) and/or compromised renal function. Closely monitor patients with known factors that predispose to convulsive activity.
Anticonvulsant therapy should be continued in patients with known seizure disorders . If CNS adverse reactions including seizures occur, evaluate patients neurologically to determine whether UTEBZI should be discontinued.
Concomitant use of carbapenems, including UTEBZI, with valproic acid or divalproex sodium may reduce the plasma concentrations of valproic acid, potentially increasing the risk of breakthrough seizures. Avoid concomitant use of UTEBZI with valproic acid and divalproex sodium . …
Tebipenem Pivoxil side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
•Hypersensitivity Reactions .
•Seizures and Other CNS Adverse Reactions .
•Carnitine Depletion .
•
Clostridioides difficile Infection (CDI) .
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of UTEBZI was evaluated in a Phase 3, double‑blind, comparator‑controlled clinical trial (Trial 1) in patients with cUTI, including pyelonephritis, in which 843 patients were treated with oral UTEBZI (600 mg every 6 hours or a renally adjusted dose) and 844 patients were treated with intravenously (IV) administered imipenem‑cilastatin (500 mg every 6 hours or a renally adjusted dose). Patients received UTEBZI for a median duration of 7.5 days and imipenem‑cilastatin for a median duration of 7.6 days.
Adverse Reactions Leading to Discontinuation
Adverse reactions leading to treatment discontinuation occurred in 0.6% (5/843) of patients receiving UTEBZI and 0.8% (7/844) of patients receiving imipenem‑cilastatin.
Common Adverse Reactions
Table 2 lists the adverse reactions occurring in ≥1% of patients receiving UTEBZI in Trial 1. …
Drug interactions
OAT1 and OAT3 Transporter Inhibitors
Concomitant use of UTEBZI and organic anion transporter 1 (OAT1) and 3 (OAT3) inhibitors is generally not recommended. If concomitant use with UTEBZI is necessary, monitor more frequently for adverse reactions associated with UTEBZI (e.g., diarrhea and headache) . Tebipenem is an OAT1 and OAT3 substrate and concomitant use of OAT1 and OAT3 transporter inhibitor drugs (e.g., probenecid) with UTEBZI results in increased tebipenem plasma concentrations .
Valproic Acid
Avoid concomitant use of UTEBZI and valproic acid or divalproex sodium. If concomitant use of UTEBZI is necessary, monitoring of valproic acid serum concentrations is recommended, and supplemental anticonvulsant therapy should be considered. Concomitant use of carbapenems, including UTEBZI, with valproic acid or divalproex sodium may reduce valproic acid plasma concentrations below the therapeutic range, increasing the risk of breakthrough seizures. The mechanism of this interaction has not been established .
Other Pivalate-Generating Drugs
Concomitant use of UTEBZI and other pivalate‑generating drugs is generally not recommended. …
About this medicine
UTEBZI (tebipenem pivoxil) tablets, for oral use, contain tebipenem pivoxil hydrobromide, the hydrobromide salt of tebipenem pivoxil, a prodrug of tebipenem, a carbapenem antibacterial. The chemical name is (pivaloyloxy)methyl (4R,5S,6S)-3-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicylo[3.2.0]hept-2-ene-2-carboxylate hydrobromide. The empirical formula is C22H32BrN3O6S2 and the molecular weight is 578.54 g/mol. The structural formula of tebipenem pivoxil hydrobromide is shown below:
Tebipenem pivoxil hydrobromide is a white to off-white powder and is sparingly soluble in water.
Each film‑coated UTEBZI tablet contains 300 mg tebipenem pivoxil, present as 348.8 mg tebipenem pivoxil hydrobromide and the following inactive ingredients: crospovidone, magnesium stearate, microcrystalline cellulose, and silicon dioxide. The tablet film‑coating consists of FD&C blue 1, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, and yellow iron oxide.
How it works: Tebipenem pivoxil is a prodrug of tebipenem, an antibacterial drug . …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f0511453-5f6f-4e3a-b7d0-a5cfde985656. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin